For the quarter ending 2026-03-31, ENTX had -$10,879K decrease in cash & cash equivalents over the period. $2,527K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-09-30 |
|---|---|---|
| Effect of exchange rate changes on cash | - | 29 |
| Net loss | 4,918 | -8,423 |
| Depreciation | -16 | 23 |
| Share-based compensation | -1,368 | 2,040 |
| The amount of finance income (expenses), net | -14 | 8 |
| Increase in other current assets | -125 | 219 |
| Decrease (increase) in accounts receivable | - | -126 |
| Increase (decrease) in accounts payable | -258 | 84 |
| Increase (decrease) in accrued liabilities and other operating liabilities | -842 | 840 |
| Net cash provided by (used in) operating activities | 2,447 | -5,537 |
| Purchase of property and equipment | -80 | 80 |
| Net cash provided by (used in) investing activities | 80 | -80 |
| Proceeds from issuance of common stock | -6,254 | 6,254 |
| Issuance cost | -262 | 262 |
| The amount represents proceeds from issuance of shares under collaboration agreement | -7,190 | 7,190 |
| Proceeds from stock options exercised | 130 | - |
| Proceeds from warrant exercises | -354 | 354 |
| Net cash provided by (used in) financing activities | -13,406 | 13,536 |
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), excluding exchange rate effect, including discontinued operation | -10,879 | 7,919 |
| Cash, cash equivalents and restricted deposits at end of the period | 14,973 | 8,740 |
| Cash, cash equivalents and restricted deposits at end of the period | 12,017 | 16,688 |
Entera Bio Ltd. (ENTX)
Entera Bio Ltd. (ENTX)